Our method could also be easily employed with animal models of cerebellar defects and diseases, such as Cbln1-null mice [57], En2-null mice [58], and cerebellar ataxia mice [59], and allow for the fast screening of interventions or drug treatments in these disease models. This evidence concerns the gene EN2 and aceruloplasminemia.